# Vaxart, Inc.: Form 10-Q for the period ended Dec 31, 2013

- Company: [Vaxart, Inc.](/companies/vxrt.md) (CIK 72444)
- Form: 10-Q
- Filed: 2014-02-10
- Accepted by EDGAR: Feb 10, 2014, 16:51 ET
- Period: 2013-12-31
- Accession: 0001437749-14-001821
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/72444/000143774914001821/bota20131231_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/72444/000143774914001821/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-10-01 to 2013-12-31 | $18.5m | us-gaap:Revenues |
| Revenue | 6 months, 2013-07-01 to 2013-12-31 | $30.8m | us-gaap:Revenues |
| Cost of revenue | 6 months, 2013-07-01 to 2013-12-31 | $22.2m | us-gaap:CostOfServices |
| Research and development | 3 months, 2013-10-01 to 2013-12-31 | $4.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2013-07-01 to 2013-12-31 | $7.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2013-10-01 to 2013-12-31 | −$100.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2013-07-01 to 2013-12-31 | −$4.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 6 months, 2013-07-01 to 2013-12-31 | −$100.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-10-01 to 2013-12-31 | −$100.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2013-07-01 to 2013-12-31 | −$4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-10-01 to 2013-12-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2013-07-01 to 2013-12-31 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2013-10-01 to 2013-12-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2013-07-01 to 2013-12-31 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2013-10-01 to 2013-12-31 | 28,291,665 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2013-07-01 to 2013-12-31 | 28,286,404 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2013-07-01 to 2013-12-31 | −$14.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2013-07-01 to 2013-12-31 | $100.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2013-12-31 | $51.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-12-31 | $79.3m | us-gaap:AssetsCurrent |
| Total assets | at 2013-12-31 | $82.7m | us-gaap:Assets |
| Current liabilities | at 2013-12-31 | $18.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-12-31 | $18.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2013-12-31 | $64.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 34,906 characters.

### FORWARD LOOKING STATEMENTS

*This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In most cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “forecast,” “potential,” “likely” or “possible”, as well as the negative of such expressions, and similar expressions intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to:*

- *our plans to continue the clinical development of laninamivir octanoate, including the ongoing Phase 2 IGLOO clinical trial and other Phase 1 trials;*
- *our ability to achieve our goal of completing the ongoing IGLOO trial by the end of the influenza season in the Northern Hemisphere;*
- *our intended use of net proceeds from the recent public offering of our common stock;*
- *future charges that we may incur related to the suspension of our antibiotic program;*
- *our future cost structure;*
- *our anticipation that revenue and the related cost of providing services under the BARDA contract will continue to increase in the near-future, assuming the program continues to advance further into clinical development;*
- *our anticipation that we will generally incur future net losses from operations due to our intention to continue to support the preclinical and clinical development of our product candidates;*
- *our future financing requirements, the factors that may influence the timing and amount of these requirements, and our ability to fund them;*
- *the number of months that our current cash, cash equivalents and anticipated future proceeds from existing royalty-bearing licenses, our contract with BARDA, and other existing license and collaboration agreements will allow us to operate; and*
- *our plan to continue to finance our operations with our existing cash, cash equivalents and proceeds from existing or potential future royalty-bearing licenses, government contracts, or collaborative research and development arrangements or through future equity and/or debt financings or other financing vehicles.*

*These statements reflect our current views with respect to future events and are based on assumptions and subject to key risks and uncertainties including, without limitation: BARDA, or we, not terminating or significantly amending our existing contract to develop laninamivir octanoate in the U.S.; GSK or Daiichi Sankyo continuing to generate net sales from Relenza® and Inavir®, respectively, and otherwise continuing to fulfill their obligations under our royalty-bearing license agreements with them in the future; we, BARDA, the FDA or similar foreign regulatory agency, a data safety monitoring board, or an institutional review board, delaying, limiting, suspending or terminating the clinical development of laninamivir octanoate at any time due to a lack of safety, tolerability, anti-viral activity, commercial viability, regulatory or manufacturing issues, or any other reason whatsoever; the results of research activities related to our product candidates being unfavorable, delayed or terminated; the safety or efficacy data from ongoing or future preclinical studies of any of our product candidates not supporting further development of that product candidate; our capacity to successfully manage worldwide clinical trials on a timely basis; our ability to comply with extensive government regulations in various countries and regions that we expect to conduct clinical trials in that are applicable to our business; our ability to maintain and or recruit sufficient human resources, including executive management and key employees; our ability to secure, manage and retain qualified third-party clinical research, preclinical research, data management and contract manufacturing organizations who we rely on to assist us in the design, development and implementation of the clinical and preclinical development of our product candidates, including laninamivir octanoate; third-party contract research, data management and manufacturing organizations continuing to fulfill their contractual obligations or otherwise performing satisfactorily in the future; our ability to manufacture and maintain sufficient quantities of preclinical and clinical trial material on hand to complete our preclinical studies or clinical trials on a timely basis; our ability, or that of our clinical research organizations or clinical investigators to recruit and enroll a sufficient number of patients in our clinical trials on a timely basis; the ability of the principal investigators participating in the ongoing IGLOO trial to correctly diagnose patients with influenza A and B; the severity and seasonality of influenza in regions where we are conducting our clinical trial of laninamivir octanoate; our failure to obtain regulatory approval to advance the clinical development of or to market our product candidates; our ability to protect and maintain our proprietary intellectual property rights from unauthorized use by others or not infringe on the intellectual property rights of others; the U.S. government defaulting on its funding obligations to BARDA; a prolonged shutdown of the U.S. government that delays or suspends the development of laninamivir octanoate, including approved cash payments to us; the condition of the financial equity and debt markets and our ability to raise sufficient funding in such markets; our ability to successfully manage our expenses, operating results and financial position in line with our plans and expectations; changes in general economic business or competitive conditions related to industry or product candidates; and other statements contained elsewhere in this Quarterly Report on Form 10-Q (including the “Risk Factors” in Part II, Item 1A of this Quarterly Report).*

*There may be events in the future that we are unable to predict accurately, or over which we have no control. You should completely read this Form 10-Q and the documents that we reference herein and that have been filed or incorporated by reference as exhibits and with the understanding that our actual future results may be materially different from what we expect. Our business, financial condition, results of operations, and prospects may change. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. We qualify all of the information presented in this Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.*

*Biota is a registered trademark of Biota Holdings Limited, Relenza® is a trademark of GlaxoSmithKline plc, Inavir® is a registered trademark of Daiichi Sankyo Company, Ltd, and TwinCaps® is a registered trademark of Hovione FarmaCiencia SA.*

*The following is a discussion and analysis of the major factors contributing to results of operations for the three and six months ended December 31, 2013, and our financial condition at that date, and should be read in conjunction with the financial statements and the notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q.*

### Company Overview

We are a biopharmaceutical company focused on the discovery and development of innovative anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases. We were incorporated in the state of Delaware in 1969, and our corporate headquarters are located in Alpharetta, Georgia.

We are currently focused on developing oral, small molecule compounds to treat a number of respiratory-related infections. Our most advanced clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor we are developing for the treatment of influenza A and B. We are currently enrolling patients in a multi-national Phase 2 trial for laninamivir octanoate, which we refer to as “IGLOO.” We also have a Phase 2 compound named vapendavir, which is in clinical development for the treatment of human rhinovirus (“HRV”) infections in patients with asthma. In addition to these clinical stage development programs we are developing an orally bioavailable compounds for the treatment of respiratory syncytial (“RSV”) infections in children, the elderly, and immune-compromised patients.

We previously developed zanamivir, a neuraminidase inhibitor, which is marketed worldwide by GlaxoSmithKline (“GSK”) as Relenza® for the prevention and treatment of influenza A and B. GSK developed and markets Relenza® pursuant to a royalty-bearing research and license agreement we entered into with GSK in 1990. In 2003, we entered into a collaboration and license agreement with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), under which each party cross-licensed its intellectual property related to second-generation long acting neuraminidase inhibitors, including FLUNET and laninamivir octanoate. In 2009, we entered into a separate commercialization agreement with Daiichi Sankyo, which provided Daiichi Sankyo an exclusive license to laninamivir octanoate in Japan and entitled us to a royalty on net sales of laninamivir octanoate in Japan. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza A and B in adults and children and, in December 2013, it was approved for the prevention of influenza A and B in Japan. Laninamivir octanoate is marketed in Japan by Daiichi Sankyo as Inavir®. In 2009, we filed an Investigational New Drug application (“IND”) with the United States Food and Drug Administration (“FDA”) to develop laninamivir octanoate in the United States. In 2011, we were awarded a contract from the U.S. Office of Biomedical Advanced Research and Development Authority (“BARDA”) designed to provide up to $231 million in support of the development of and submission for a new drug application of laninamivir octanoate for the treatment of influenza A and B infections in the United States. In June 2013, we initiated a Phase 2 clinical trial of laninamivir octanoate under this IND. In November 2013, we initiated two Phase 1 studies of laninamivir octanoate to assess safety and pharmacokinetics of laninamivir octanoate in adults with mild to moderate chronic asthma and a QT/QTc study designed to evaluate the effect of therapeutic and supra-therapeutic doses of laninamivir octanoate on cardiac ventricular repolarization. In December 2013, we announced that we have commenced dosing patients in the Northern Hemisphere portion of the ongoing Phase 2 IGLOO clinical trial for laninamivir octanoate.

Although several of our influenza product candidates have been successfully developed and commercialized by other larger pharmaceutical companies under collaboration, license or commercialization agreements with us, we have not independently developed or received regulatory approval for any product candidate, and we do not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that we may not successfully derive any significant product revenues from any of our existing or future development-stage influenza or other product candidates that we are developing now, or may develop in the future. We expect to incur losses for the foreseeable future as we intend to support the clinical and preclinical development of our product candidates.

### Recent Corporate Developments

*Public Offering –* In January 2014, we reported that we had priced a public offering of 5,813,900 shares of our common stock at a purchase price of $4.30 per share. Later in January, we further reported that the underwriter had exercised its option to purchase 872,085 additional shares at the public offering price to cover over-allotments. The net proceeds to us from the sale of the shares, including the overallotment, after underwriting discounts and commissions and other offering expenses, were approximately $26.9 million. We intend to use the net proceeds from the offering for working capital and general corporate purposes.

*Laninamivir Octanoate –* In November 2013, we reported that we commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate. The trial, referred to as “IGLOO”, compares the safety and efficacy of 40 mg and 80 mg of laninamivir octanoate with placebo, all delivered by a TwinCaps® inhaler in adults with symptomatic influenza A or B infection. In February, 2014 we reported that we have enrolled over 60% of the 636 subjects targeted for the trial; however, the rate of PCR-confirmed influenza patients is trending lower than we originally planned. In the event the PCR-confirmed rate remains below planned levels, we believe it will become challenging to achieve our goal of completing the IGLOO trial by the end of the influenza season in the Northern Hemisphere.

In November 2013, we also reported that we had initiated two additional Phase 1 clinical trials of laninamivir octanoate; one to evaluate its safety and pharmacokinetics of in patients with chronic asthma and one being a QT/QTc study to evaluate effect of therapeutic and supra-therapeutic doses of laninamivir octanoate on the QT-interval in healthy volunteers. We have also initiated a Phase 1/2 clinical trial of laninamivir octanoate in pediatric patients, aged 5-17, infected with influenza. All three trials are ongoing.

In December, 2013, we reported that Daiichi Sankyo was granted regulatory approval in Japan to manufacture and market Inavir® Dry Powder Inhaler 20mg (generic name laninamivir octanoate) for the prevention of influenza A and B. Inavir® was successfully developed and launched by Daiichi Sankyo in Japan for the treatment of influenza A and B viruses in October, 2010.

*Operations –* In November 2013, our Board of Directors adopted a change in our operations whereby we suspended further investment in our preclinical antibiotic program and indicated we would seek collaborations, license agreements or other transactions to advance the development of this program and the associated intellectual property. We estimated at that time that we could incur up to $2.9 million in total costs associated with the related termination, exit or disposal activities, including up to $2.0 million in one-time termination benefits during the second and third quarters of our 2014 fiscal year.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Management’s Discussion and Analysis of Results of Operations discusses our financial results, which (except to the extent described in the Notes thereto) have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

We base our estimates and judgments on historical experience, current economic and industry conditions, and various other factors that we believe to be reasonable under the circumstances. This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies require significant judgment and estimates:

- Use of Estimates
- Revenue Recognition
- Accrued Expenses
- Share-Based Compensation

In March 2013, the FASB issued ASU No. 2013-05, and we do not anticipate the future adoption of ASU 2013-05 will have a material impact on our consolidated financial statements.

### Results of Operations

### Three Months Ended December 31, 2013 and December 31, 2012

*Summary.* We reported a net loss of $0.1 million for the three month period ended December 31, 2013, as compared to a net income of $4.6 million in the same period of 2012. The $4.7 million increase in net loss from 2012 to 2013 was primarily the result of a non-operating gain of $7.8 million recorded in 2012 as a result of the merger in November 2012, the receipt of a $4.4 million research and development credit that was not received in 2013, an increase of $4.3 million in cost of revenue expense, a decrease in foreign exchange gain of $0.5 million, and a $0.4 million decrease in interest income, offset in part by $8.1 million increase in revenue, a $0.4 million decrease in research and development expense, and a $4.0 million decrease in general and administrative expense. Basic and diluted net loss per share were $0.00 for the three month period ended December 31, 2013, as compared to a basic and diluted net income per share of $0.16 in the same period of 2012.

We generally expect to incur losses for the foreseeable future as we intend to continue to support the clinical development of laninamivir octanoate and the development of our programs.

*Revenue.* Revenue increased to $18.5 million for the three months ended December 31, 2013 from $10.4 million for the same period in 2012. The following table summarizes the key components of our revenue for the three months ended December 31, 2013 and 2012:

|  | Three Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Royalty revenues– Relenza® | $5.4 | $1.0 |
| – Inavir® | 0.6 | 0.9 |
| Revenue from services | 12.4 | 8.1 |
| Other | 0.1 | 0.4 |
| Total revenue | $18.5 | $10.4 |

Royalty revenues increased due to higher sales of Relenza during the quarter. Revenue from services increased primarily due to increased service revenue under the BARDA contract from the ongoing Phase 2 and Phase 1clinical trials of laninamivir octanoate and related manufacturing activities. Other revenue decreased due to lower research activities related to grants.

*Cost of Revenue.* Cost of revenue increased to $11.4 million for the three months ended December 31, 2013 from $7.1 million for the same period in 2012. The following table summarizes the components of our cost of revenue for the three months ended December 31, 2013 and 2012.

|  | Three Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Direct preclinical, clinical and product development expense | $10.1 | $5.8 |
| Salaries, benefits and share-based compensation expense | 1.2 | 1.2 |
| Other expense | 0.1 | 0.1 |
| Total cost of revenue expense | $11.4 | $7.1 |

20

Direct preclinical, clinical and product development expense increased in 2013 due to the ongoing Phase 2 and Phase 1 clinical trials for laninamivir octanoate, as well as related manufacturing activities under the BARDA contract.

*Research and Development Expense.* Research and development expense decreased to $4.2 million for the three months ended December 31, 2013 from $4.6 million for the same period in 2012. The following table summarizes the components of our research and development expense for the three months ended December 31, 2013 and 2012.

|  | Three Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Direct preclinical, clinical and product development expense | $0.5 | $0.4 |
| Salaries, benefits and share-based compensation expense | 2.7 | 2.1 |
| Other expense | 0.4 | 1.1 |
| Depreciation and facility related expense | 0.6 | 1.0 |
| Total research and development expense | $4.2 | $4.6 |

Direct preclinical, clinical and product development expense increased in 2013 due to an increase in preclinical activities on our RSV program, offset in part by a reduction in clinical expenses associated with the completion of the Phase 2 clinical trial of vapendavir in 2012. Salaries, benefits and share-based compensation increased in 2013 due to a charge of $1.4 million that we recorded for severance obligations in November 2013, offset in part by lower recurring personnel costs as a result of the headcount reductions that occurred in April and November 2013. Other expenses decreased in 2013 due to a reduced number of research programs. Depreciation and facility related expenses decreased in 2013 due to lower depreciation and operating expenses for our research facility.

*General and Administrative Expense.* General and administrative expense decreased to $3.1 million for the three months ended December 31, 2013 from $7.1 million for the same period in 2012. The following table summarizes the components of our general and administrative expense for the three months ended December 31, 2013 and 2012.

|  | Three Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Salaries, benefits and share-based compensation expenses | $1.6 | $2.3 |
| Professional and legal fees expenses | 0.5 | 0.3 |
| Other expenses | 1.0 | 1.1 |
| Merger-related expenses | - | 3.4 |
| Total general and administrative expense | $3.1 | $7.1 |

Salaries, benefits and share-based compensation expense decreased in 2013 due to a decrease in recurring personnel costs due to headcount reductions that occurred in April 2013. Professional and legal fees increased in 2013 primarily due to higher consulting and legal expenses related to corporate matters. Other expenses decreased in 2013 due to slightly lower office expenses.

*Foreign Exchange Gain (Loss), net.* Foreign exchange gain decreased in 2013 due to the higher amount of U.S. dollar cash holdings as compared to 2012, which reduced our exposure for foreign exchange changes.

*Interest Income.* Interest income decreased in 2013 due to lower available interest rates on a higher amount of U.S. dollar cash holdings in 2013 as compared to 2012.

### Six Months Ended December 31, 2013 and December 31, 2012

*Summary.* For the six months ended December 31, 2013, we reported a net loss of $4.0 million, compared to a net loss of $2.6 million for the same period of 2012. The $1.4 million increase in net loss from 2012 to 2013 was primarily the result of a non-operating gain of $7.6 million recorded in 2012 as a result of the merger in November 2012, the receipt of a $4.4 million research and development credit in 2012 that was not received in 2013, an increase of $13.6 million in cost of revenue expense, a decrease in foreign exchange gain of $0.7 million, and a $0.9 million decrease in interest income, offset in part by $19.0 million increase in revenue, a $2.0 million decrease in research and development expense, a $4.8 million decrease in general and administrative expense. Basic and diluted net loss per share was $0.15 for the six month period ended December 31, 2013, as compared to a basic and diluted net loss per share of $0.09 in the same period of 2012.

*Revenue.* Revenue increased to $30.8 million for the six months ended December 31, 2013 from $11.8 million for the same period in 2012. The following table summarizes the key components of our revenue for the six months ended December 31, 2013 and 2012:

|  | Six Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Royalty revenue– Relenza® | $5.4 | $1.0 |
| – Inavir® | 0.6 | 0.9 |
| Revenue from services | 24.6 | 9.4 |
| Other | 0.2 | 0.5 |
| Total revenue | $30.8 | $11.8 |

Royalty revenue increased due to higher sales of Relenza during the period as compared to last year. Revenue from services increased primarily due to increased service revenues under the BARDA contract from the ongoing Phase 2 and Phase 1clinical trials of laninamivir octanoate and related manufacturing. Other revenue decreased due to lower research activities as compared to last year related to grants.

*Cost of Revenue.* Cost of revenue increased to $22.2 million for the six months ended December 31, 2013 from $8.6 million for the same period in 2012. The following table summarizes the components of our cost of revenue for the six months ended December 31, 2013 and 2012.

|  | Six Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Direct preclinical, clinical and product development expense | $19.6 | $6.3 |
| Salaries, benefits and share-based compensation expense | 2.4 | 2.1 |
| Other expense | 0.2 | 0.2 |
| Total cost of revenue expens | $22.2 | $8.6 |

Direct preclinical, clinical and product development expense increased primarily due to the ongoing phase 2 clinical trial and related manufacturing activities, as well as the Phase 1 clinical trials for laninamivir octanoate under the BARDA contract. Salaries, benefits and share-based compensation expense increased principally due to more research and development resources being deployed on the laninamivir octanoate clinical development program under the BARDA contract in 2013 than in 2012.

*Research and Development Expense.* Research and development expense decreased to $7.1 million for the six months ended December 31, 2013 from $9.1 million for the same period in 2012. The following table summarizes the components of our research and development expense for the six months ended December 31, 2013 and 2012.

|  | Six Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Direct preclinical, clinical and product development expense | $0.9 | $1.1 |
| Salaries, benefits and share-based compensation expense | 4.1 | 4.3 |
| Other expense | 0.7 | 1.9 |
| Depreciation and facility related expense | 1.4 | 1.8 |
| Total research and development expense | $7.1 | $9.1 |

Direct preclinical, clinical and product development expense decreased in 2013 due to lower direct clinical trial expenses associated with the completion of the Phase 2 clinical trial of vapendavir in 2012, offset in part by preclinical activities on our RSV program. Salaries, benefits and share-based compensation decreased in 2013 due to lower recurring personnel costs as a result of the headcount reductions that occurred in April and November 2013, offset in part by a charge of $1.4 million that we recorded for severance obligations in November 2013. Other expenses decreased in 2013 due to a reduced number of research programs. Depreciation and facility related expenses decreased in 2013 due to lower depreciation and operating expenses for our research facility.

*General and Administrative Expense.* General and administrative expense decreased to $5.5 million for the six months ended December 31, 2013 from $10.3 million for the same period in 2012. The following table summarizes the components of our general and administrative expense for the six months ended December 31, 2013 and 2012.

|  | Six Months Ended December 31 (in millions) 2013 | 2012 |
| --- | ---: | ---: |
| Salaries, benefits and share-based compensation expenses | $2.9 | $3.5 |
| Professional and legal fees expenses | 0.9 | 0.3 |
| Other expenses | 1.7 | 1.9 |
| Merger related expenses | - | 4.6 |
| Total general and administrative expense | $5.5 | $10.3 |

Salaries, benefits and share-based compensation decreased in 2013 due to a decrease in recurring personnel costs due to headcount reductions in workforce that occurred in April 2013. Professional and legal fees increased in 2013 primarily due to higher professional and legal expenses related to corporate matters. Other expenses decreased in 2013 due to slightly lower general office expenses.

*Foreign Exchange (Loss), net.* Foreign exchange loss increased in 2013 due to the decrease in value of the Australian dollar as compared to the U.S. dollar during the six month period and the related recording of the translation of foreign currency balances in our subsidiaries that have a different functional currency than our reporting currency.

*Interest Income.* Interest income decreased in 2013 due to lower available interest rates on our U.S. cash holdings in 2013 as compared to 2012.

### LIQUIDITY AND CAPITAL RESOURCES

For the six months ended December 31, 2013, cash and cash equivalents decreased by $15.4 million, from $66.8 million to $51.4 million. This decrease was primarily the result of cash used for operating activities during the period.

Net cash used in operating activities was $14.6 million for the six months ended December 31, 2013, which reflected our net loss for the period of $4.0 million, plus an increase in net operating assets of $15.5 million, offset in part by a net increase in operating liabilities of $3.0 million and non-cash charges for share-based compensation and depreciation and amortization of $1.9 million. Our net loss resulted largely from our funding of research and development activities including basic research, conducting clinical trials and preclinical studies, manufacturing and formulation activities, and incurring ongoing general and administrative expenses, offset in part by royalty revenue, contract service revenue and interest income. The net change in operating assets and liabilities of $12.5 million reflects a $16.7 million increase in accounts receivable due to increased royalty revenue and revenue from services, a decrease of $1.0 million in accrued severance obligations related to the merger and a decrease of $0.2 million in deferred revenue, offset in part by a $4.2 million increase in accounts payable and other accrued expenses and a $1.2 million decrease in prepaid expenses.

Net cash used in investing activities during the six months ended December 31, 2013 was $0.1 million for purchases of property and equipment.

At December 31, 2013, our cash and cash equivalents totaled $51.4 million. Our cash and cash equivalents are currently held in the form of short-term cash deposits with large U.S., Australian and U.K. banks.

Our future funding requirements are difficult to determine and will depend on a number of factors, including:

- the variability of future royalty revenue we may receive from existing royalty-bearing license agreements;
- whether we continue to receive sufficient revenue and the timing of the those payments under our contract with BARDA to advance the development of laninamivir octanoate in the U.S.;
- the development timelines and plans for our product candidates, including any changes to those timelines, plans or our strategy;
- the variability, timing and costs associated with conducting clinical trials for our product candidates, the rate of enrollment in such clinical trials, and the results of these clinical trials:
- the variability, timing and costs associated with conducting preclinical studies, and the results of those studies;
- the cost of scaling up, formulating and manufacturing preclinical and clinical trial materials to evaluate our product candidates;
- whether we receive regulatory approval to advance or begin the clinical development of our product candidates in a timely manner, or at all;
- the cost and time to obtain regulatory approvals required to advance the development of our product candidates;
- the scope and size of our research and development efforts;
- our pursuit, timing and the terms of any in-licensing, acquisition, co-development, and other similar collaborative clinical-stage development opportunities we may pursue in the future to better balance our pipeline;
- the size and cost of the general and administrative functions we may need to manage our operations, including the infrastructure to support being a publicly-traded company; and
- the cost of filing, prosecuting, and enforcing patent and other intellectual property claims.

Based on our current strategy and operating plan, and considering the potential costs associated with advancing the clinical development and preclinical development of our product candidates, we believe that our existing cash, cash equivalents of $51.4 million as of December 31, 2013, along with the anticipated proceeds from existing royalty-bearing licenses, our reimbursement contract with BARDA, the public offering completed in January 2014 and other existing license and collaboration agreements will enable us to operate for a period of at least 12 months from December 31, 2013.

We currently do not have any commitments for future funding, nor do we anticipate that we will generate significant revenue, aside from existing revenue from royalty-bearing arrangements, and contract services. Therefore, in order to meet our anticipated liquidity needs beyond 12 months to support the development of our product candidates, or possibly sooner in the event we enter into other transactions or revise our strategy or development plans, we may need to raise or secure additional capital. We would expect to do so primarily through the sale of additional common stock or other equity securities, as well as through proceeds from future licensing agreements, strategic collaborations, forms of debt financing, or any other financing vehicle. Funds from these sources may not be available to us on acceptable terms, if at all, and our failure to raise such funds could have a material adverse impact on our future business strategy and plans, financial condition and results of operations. If adequate funds are not available to us on acceptable terms in the future, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs, or delay or curtail our preclinical studies and clinical trials, or reduce our internal cost structure. If additional capital is not available to us on acceptable terms, we may need to obtain funds through license agreements, or collaborative or partner arrangements pursuant to which we will likely relinquish rights to certain product candidates that we might otherwise choose to develop or commercialize independently, or be forced to enter into such arrangements earlier than we would prefer, which would likely result in less favorable transaction terms. Additional equity financings may be dilutive to holders of our common stock, and debt financing, if available, may involve significant payment obligations and restrictive covenants that restrict how we operate our business.

### Contractual and Commercial Commitments

There have been no material changes from the information included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2013.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) (ii) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

## Market risk

As filed, 291 characters.

There has been no material change in the Company’s assessment of its sensitivity to market risk since its presentation set forth in Item 7A “Quantitative and Qualitative Disclosures about Market Risk” in the Company’s Annual Report filed on Form 10-K for the fiscal year ended June 30, 2013.

## Controls and procedures

As filed, 881 characters.

Our Chief Executive Officer currently acts as our Principal Financial Officer.

### Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

### Changes in Internal Controls over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended December 31, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,060 characters.

*An investment in our securities involves a risk of loss. You should carefully consider each of the following risks, together with other information in this Quarterly Report, in evaluating our business, financial condition and our prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impact our business and prospects. If any of the following risks actually occur, our business, financial condition, our ability to raise additional capital in the future could be materially harmed. In that case, the trading price of our common stock could decline, and you could lose all or part of your investment in us. You should also refer to the other information set forth in this Quarterly Report and in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 27, 2013 and our Quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2013, including our financial statements and the notes to those statements.*

***If the principal investigators in our ongoing or planned clinical studies of laninamivir octanoate, including our ongoing Phase 2 IGLOO trial, are less accurate than we estimated at the outset of a trial in diagnosing whether a subject has influenza A or B when they are enrolled in a trial, we may have to enroll more subjects in that trial than planned in order to obtain a sufficient number of patients that are confirmed to have influenza A and B, which could materially extend the duration or increase the cost of the trial, and harm our business prospects.***

Influenza symptoms are in many cases similar to those of the common cold or other types of respiratory infections. Where the purpose of a clinical trial includes evaluating the potential effectiveness or activity of laninamivir octanoate in patients that are infected with influenza A and B, such trials will generally be designed so that subjects are enrolled into the trial by our principal investigators based on their diagnosis of the subject’s medical symptoms at the time of enrollment. In order to verify this diagnosis, we conduct a polymerase chain reaction (“PCR”) test on each subject to confirm whether the subject tests positive for influenza A or B (“PCR positive”), the results of which do not become available to us for approximately two or three weeks after the subject is enrolled. If the subject ultimately is not PCR positive for influenza A or B, the data from that subject will not be included in the evaluation of the potential effectiveness or activity of laninamivir octanoate in that trial, but will be included in its safety and tolerability assessment. If the percentage, or rate, of subjects that are PCR positive in such a trial is less than what we estimated in the design and outset of the trial, we may have to enroll additional patients in the trial to achieve the number of PCR positive patients we intended to enroll in the trial.

Filed Feb 10, 2014.
Source: SEC EDGAR, the filing index for accession 0001437749-14-001821. Last ingested by Listed: Nov 5, 2026, 18:48 ET. No prices; not investment advice.
